2 domains / 4 areas / 3 specializations
Field Trip Health
Data updated
Field Trip Health was a Canadian publicly traded ketamine-assisted psychotherapy company founded in 2019 that operated clinics across North America and Europe while developing FT-104, a shorter-duration psilocybin analog, before a 2023 financial restructuring under Canada's Companies' Creditors Arrangement Act. Its drug development assets were spun off as Reunion Neuroscience (which raised $103M Series A in 2024) while its US clinic network was acquired by Stella and its Canadian clinics by the Canadian Centre for Psychedelic Healing.
Academic Research
0 papersPublished Papers
0
Trial Involvement
1
Distinct Focus Topics
0
Latest Publication
Unknown
Clinical Care Delivery Snapshot
Virtual & Hybrid Care ProvidersProvider Model
Hybrid Provider Network
Organization Status
Unknown
Psychedelic Services
Ketamine-Only Services
Service Coverage
National
Service Profile
Care Settings
Service Modalities
Payer Models
Non-Psychedelic Service Mix
Mental Health Adjacent Services
Quick Facts
- Type
- Public Biotech
- HQ
- Canada
- Website
- Visit